Healthcare Focus Oberland Capital is a healthcare focused private investment firm with over $3 billion in assets under management, offering flexible financing options including royalty monetization, future product revenue purchases, project based financing, and traditional debt or equity. This makes them a strong partner for biotech and pharmaceutical companies seeking non-dilutive, milestone driven capital or bespoke funding structures aligned to product development timelines.

Oncology Momentum Recent deals show a heavy emphasis on oncology asset monetization and strategic financing, including Verastem's $7.5 million equity investment with a $150 million credit facility and an IQVIA market access partnership; ImmunityBio's up to $320 million royalty and equity investment; and Curis royalty asset sales. These signals suggest Oberland is actively targeting oncology programs that can benefit from royalty monetization and flexible capital solutions.

Flexible Financing Their financing toolkit includes royalty stream monetization, acquisition of future product revenues, project based financing structures, and traditional debt/equity investments. This suite is well suited for companies with upcoming milestones, uneven cash flows, or a desire for non-dilutive funding to advance products.

Data Driven The team expansion into quantitative research and investor relations, with hires in 2023-2024, indicates a data driven approach to deal structuring and partner management. This can appeal to science and finance teams seeking rigorous, transparent financing proposals and milestone based performance metrics.

Strategic Fit With NYC headquarters, a global healthcare focus, and mid-market scale (revenue in the $50-100 million range and 11-50 employees), Oberland offers a credible, scalable capital partner for mid-stage biotechs and asset divestitures. Leverage recent deal activity and partnerships (IQVIA, Verastem, ImmunityBio, Curis) to tailor outreach for royalty monetization or product-revenue financing.